AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26445486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Written + Tailored Video (TW + TV)
Number of subjects: 2525
Study 26445486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Written (TW)
Number of subjects: 2525
Study 23551983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol/midazolam
Number of subjects: 348
Study 23551983 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral melatonin/hydroxyzine/lorazepam
Number of subjects: 348
Study 21659891 — intervention group
Group type: EXPERIMENTAL
Intervention: HiMF training (HiMFT)
Number of subjects: 55
Study 21659891 — intervention group
Group type: EXPERIMENTAL
Intervention: LoMF training (LoMFT)
Number of subjects: 55
Study 21659891 — intervention group
Group type: COMPARATOR
Intervention: HiMF control (HiMFC)
Number of subjects: 55
Study 21659891 — intervention group
Group type: COMPARATOR
Intervention: LoMF control (LoMFC)
Number of subjects: 55
Study 17933414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg
Number of subjects: 151
Study 17933414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 17073156 — intervention group
Group type: EXPERIMENTAL
Intervention: Aralox phytopreparation containing Aralia mandshurica and Engelhardtia chrysolepis extracts
Number of subjects: 32
Study 12774016 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ng/kg IL-12 subcutaneously twice weekly for 12 weeks
Number of subjects: 225
Study 12774016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 12774016 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12 therapy
Number of subjects: 225
Study 11200372 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcus faecium probiotic (150 ml daily, 4.5 x 10^9 to 7.5 x 10^9 CFU E. faecium for 10 days)
Number of subjects: 40
Study 11200372 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg orally q.i.d. for 10 days)
Number of subjects: 40
Study 11200372 — intervention group
Group type: COMPARATOR
Intervention: VRE detection in volunteers
Number of subjects: 40
Study 9357377 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol by Ventolin metered-dose inhaler (2 puffs, 90 micrograms/puff)
Number of subjects: 12
Study 9357377 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol sulfate powder (Rotacaps) by dry powder inhaler (2 inhalations, 100 micrograms/puff)
Number of subjects: 12
Study 9357377 — intervention group
Group type: COMPARATOR
Intervention: Lactose powder by dry powder inhaler (2 inhalations, 12.5 mg/inhalation)
Number of subjects: 12
Study 1588824 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg
Number of subjects: 10
Study 1588824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2862995 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with low‐dose continuous prednisone (7.5 mg daily)
Number of subjects: 505
Study 2862995 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy without prednisone
Number of subjects: 505
Study 2862995 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced amenorrhea
Number of subjects: 505
Study 29126203 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily) with radiation therapy and concurrent/adjuvant temozolomide
Number of subjects: 171
Study 29126203 — intervention group
Group type: COMPARATOR
Intervention: Control (radiation therapy with concurrent and adjuvant temozolomide without everolimus)
Number of subjects: 171
Study 26714774 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3FA lovaza 4 g
Number of subjects: 266
Study 26714774 — intervention group
Group type: EXPERIMENTAL
Intervention: raloxifene 60 mg
Number of subjects: 266
Study 26714774 — intervention group
Group type: EXPERIMENTAL
Intervention: raloxifene 30 mg
Number of subjects: 266
Study 26714774 — intervention group
Group type: EXPERIMENTAL
Intervention: lovaza 4 g plus raloxifene 30 mg
Number of subjects: 266
Study 26714774 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 266
Study 24661672 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (RT)
Number of subjects: 136
Study 24661672 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 136
Study 22908115 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fortified with 300 IU of vitamin D(3) (n = 143)
Number of subjects: 247
Study 22908115 — intervention group
Group type: COMPARATOR
Intervention: Unfortified regular milk (control; n = 104)
Number of subjects: 247
Study 22908115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 247
Study 19697119 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Attention Training (CAT)
Number of subjects: 77
Study 19697119 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction (CAI)
Number of subjects: 77
Study 19697119 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 19087949 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Ending (HE) smoking cessation program
Number of subjects: 290
Study 19087949 — intervention group
Group type: COMPARATOR
Intervention: Control group (44-page self-help booklet)
Number of subjects: 290
Study 15885299 — intervention group
Group type: EXPERIMENTAL
Intervention: O'Brien‐Fleming stopping method
Number of subjects: 0
Study 15885299 — intervention group
Group type: EXPERIMENTAL
Intervention: Peto group sequential stopping method
Number of subjects: 0
Study 14512132 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% ophthalmic solution
Number of subjects: 73
Study 14512132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate monohydrate 50-microg nasal spray
Number of subjects: 73
Study 14512132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride 180-mg tablets
Number of subjects: 73
Study 14512132 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 73
Study 14512132 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 73
Study 14512132 — intervention group
Group type: COMPARATOR
Intervention: Placebo topical solution
Number of subjects: 73
Study 10098806 — intervention group
Group type: EXPERIMENTAL
Intervention: Striking a reinforced structure with a 4.54 kg sledge hammer
Number of subjects: 20
Study 10098806 — intervention group
Group type: EXPERIMENTAL
Intervention: Striking a weighted truck tire with a 4.54 kg sledge hammer
Number of subjects: 20
Study 10098806 — intervention group
Group type: EXPERIMENTAL
Intervention: Striking a reinforced structure with a 5.60 kg sledge hammer
Number of subjects: 20
Study 10098806 — intervention group
Group type: EXPERIMENTAL
Intervention: Striking a weighted truck tire with a 5.60 kg sledge hammer
Number of subjects: 20
Study 8901655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Integrelin (90 micrograms/kg bolus followed by 1.0 microgram.kg‐1.min‐1 continuous infusion)
Number of subjects: 227
Study 8901655 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 227
Study 8901655 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Integrelin (45 micrograms/kg bolus followed by 0.5 microgram.kg‐1.min‐1 continuous infusion)
Number of subjects: 227
Study 8901655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 1809429 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) morphine
Number of subjects: 38
Study 1809429 — intervention group
Group type: COMPARATOR
Intervention: p.r.n. intravenous morphine
Number of subjects: 38
Study 6882604 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 8
Study 6882604 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (during treatment)
Number of subjects: 8
Study 6882604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31444917 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer-based thermo-sensitive sol-gel instillation
Number of subjects: 198
Study 31444917 — intervention group
Group type: COMPARATOR
Intervention: Lubricant instillation (Control)
Number of subjects: 198
Study 30989380 — intervention group
Group type: COMPARATOR
Intervention: Resting heart rate (RHR) > 80 bpm
Number of subjects: 16201
Study 30989380 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted genetic risk score (GRS) for RHR
Number of subjects: 16201
Study 30989380 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resting heart rate
Number of subjects: 16201
Study 28281052 — intervention group
Group type: EXPERIMENTAL
Intervention: MOBIDERM® Autofit (night-use group)
Number of subjects: 40
Study 28281052 — intervention group
Group type: COMPARATOR
Intervention: No night-use group (control)
Number of subjects: 40
Study 28281052 — intervention group
Group type: EXPERIMENTAL
Intervention: MOBIDERM® Autofit (after Day 30 for all patients)
Number of subjects: 40
Study 28281052 — intervention group
Group type: EXPERIMENTAL
Intervention: MOBIDERM® Autofit
Number of subjects: 40
Study 27434918 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis group (RPD)
Number of subjects: 376
Study 27434918 — intervention group
Group type: COMPARATOR
Intervention: No aid group
Number of subjects: 376
Study 24841163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC) 320 μg once daily
Number of subjects: 150
Study 24841163 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) 200 μg two inhalations twice daily
Number of subjects: 150
Study 24841163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC)
Number of subjects: 150
Study 22007656 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb exercises followed by manual therapy (MT)
Number of subjects: 131
Study 22007656 — intervention group
Group type: COMPARATOR
Intervention: Upper limb exercises alone
Number of subjects: 131
Study 19707090 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal digital assistant-based log with obesity decision support features
Number of subjects: 1874
Study 19707090 — intervention group
Group type: COMPARATOR
Intervention: Personal digital assistant-based log without obesity decision support features
Number of subjects: 1874
Study 17312210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex, 4 mg/kg IV (n = 20)
Number of subjects: 60
Study 17312210 — intervention group
Group type: COMPARATOR
Intervention: Edrophonium, 1 mg/kg IV and atropine, 10 microg/kg IV (n = 20)
Number of subjects: 60
Study 17312210 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine, 70 microg/kg IV and glycopyrrolate, 14 microg/kg IV (n = 20)
Number of subjects: 60
Study 17312210 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine-glycopyrrolate group
Number of subjects: 60
Study 17312210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex group
Number of subjects: 60
Study 15802292 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (L-NMMA) infusion
Number of subjects: 21
Study 15802292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 21
Study 15802292 — intervention group
Group type: COMPARATOR
Intervention: Baseline leg vascular resistance measurement
Number of subjects: 21
Study 11782752 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboMedics
Number of subjects: 485
Study 11782752 — intervention group
Group type: COMPARATOR
Intervention: St Jude Medical
Number of subjects: 485
Study 9852985 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka strain) at 3200 pfu/dose
Number of subjects: 200
Study 9852985 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka strain) at 8500 pfu/dose
Number of subjects: 200
Study 9852985 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated VZV vaccine (Oka strain) at 41,650 pfu/dose
Number of subjects: 200
Study 9852985 — intervention group
Group type: COMPARATOR
Intervention: Control pneumococcal polysaccharide vaccine
Number of subjects: 200
Study 8184803 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 919
Study 8184803 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 919
Study 3141301 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg tablet)
Number of subjects: 93
Study 3141301 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (250 mg injection)
Number of subjects: 93
Study 31462695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 113
Study 31462695 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 28960777 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP
Number of subjects: 1853
Study 28960777 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT
Number of subjects: 1853
Study 28960777 — intervention group
Group type: EXPERIMENTAL
Intervention: MR‐proADM
Number of subjects: 1853
Study 28960777 — intervention group
Group type: EXPERIMENTAL
Intervention: copeptin
Number of subjects: 1853
Study 28960777 — intervention group
Group type: EXPERIMENTAL
Intervention: cystatin C
Number of subjects: 1853
Study 28960777 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 1853
Study 28111051 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based interactive education platform
Number of subjects: 2226
Study 28111051 — intervention group
Group type: EXPERIMENTAL
Intervention: Document education group
Number of subjects: 2226
Study 28111051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2226
Study 25639198 — intervention group
Group type: EXPERIMENTAL
Intervention: DISE plus MM (19 patients)
Number of subjects: 39
Study 25639198 — intervention group
Group type: COMPARATOR
Intervention: MM only (20 patients)
Number of subjects: 39
Study 23307675 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) introduced into the tunnels peri-operatively
Number of subjects: 50
Study 23307675 — intervention group
Group type: COMPARATOR
Intervention: No PRP introduced into the tunnels (Control)
Number of subjects: 50
Study 21676232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) in 28 fractions delivering 50.4 Gy to the breast and 64.4 Gy to the tumor bed by integrated boost
Number of subjects: 502
Study 21676232 — intervention group
Group type: COMPARATOR
Intervention: Conventional Radiotherapy in 28 fractions to a dose of 50.4 Gy and consecutive boost in 8 fractions to a total dose of 66.4 Gy
Number of subjects: 502
Study 18224474 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon performed ultrasound (SUS)
Number of subjects: 218
Study 18224474 — intervention group
Group type: COMPARATOR
Intervention: Radiologist performed ultrasound (RUS)
Number of subjects: 218
Study 16525138 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg once daily for a minimum of 52 weeks
Number of subjects: 648
Study 16525138 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg once daily for a minimum of 52 weeks
Number of subjects: 648
Study 16525138 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 648
Study 16525138 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 648
Study 14633754 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacaine 0.2% 5 ml h(‐1) for 55 h after infiltration with ropivacaine 0.5% 40 ml.
Number of subjects: 37
Study 14633754 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia with continuous i.v. infusion of morphine plus ketorolac for 24 h followed by saline infusion for 55 h.
Number of subjects: 37
Study 11602412 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided dosing
Number of subjects: 1251
Study 11602412 — intervention group
Group type: COMPARATOR
Intervention: Control group (expert physicians without algorithms)
Number of subjects: 1251
Study 9580382 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (8 weeks of open‐label treatment)
Number of subjects: 15
Study 8306022 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal CO2 removal
Number of subjects: 40
Study 8306022 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 40
Study 8306022 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient survival
Number of subjects: 40
Study 2493798 — intervention group
Group type: EXPERIMENTAL
Intervention: Bain system
Number of subjects: 20
Study 2493798 — intervention group
Group type: COMPARATOR
Intervention: ADE system
Number of subjects: 20
Study 31912685 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemoradiotherapy (CCRT)
Number of subjects: 316
Study 31912685 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy (RT) alone
Number of subjects: 316
Study 31382965 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 31382965 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study 31382965 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 28796940 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered depression care management (DCM)
Number of subjects: 628
Study 28796940 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 628
Study 26656642 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (first dose)
Number of subjects: 72
Study 26656642 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures of CANTAB tests (PAL, PRM, CRT)
Number of subjects: 72
Study 23490304 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 196
Study 23490304 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Counseling Intervention (BCI)
Number of subjects: 196
Study 23490304 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 196
Study 23490304 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Therapy (BBCET)
Number of subjects: 196
Study 21785369 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 177
Study 21785369 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Work Hours (RWH)
Number of subjects: 177
Study 21785369 — intervention group
Group type: COMPARATOR
Intervention: Referents (Control)
Number of subjects: 177
Study 19537033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (4 x 10^6 U in 100 ml normal saline infused intravenously for 30 min since skin incision, with additional 2 x 10^6 U infused at a rate of 4-6 x 10^4 U x h(-1) until chest closure)
Number of subjects: 36
Study 19537033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 36
Study 19537033 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 ml normal saline without ulinastatin)
Number of subjects: 36
Study 16428534 — intervention group
Group type: EXPERIMENTAL
Intervention: J‐Tip with 0.25 mL of 1% buffered lidocaine (n = 57)
Number of subjects: 116
Study 16428534 — intervention group
Group type: COMPARATOR
Intervention: EMLA with 2.5 g (n = 59)
Number of subjects: 116
Study 14971232 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaxem Hib
Number of subjects: 331
Study 14971232 — intervention group
Group type: COMPARATOR
Intervention: HibTITER
Number of subjects: 331
Study 11575224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercury or aneroid sphygmomanometer
Number of subjects: 3388
Study 11575224 — intervention group
Group type: COMPARATOR
Intervention: SECURUS manometer
Number of subjects: 3388
Study 9038285 — intervention group
Group type: COMPARATOR
Intervention: Listening to frequent low- or rare high-pitched tones (LIS)
Number of subjects: 17
Study 9038285 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective auditory attention to deviants in one ear (ATTR)
Number of subjects: 17
Study 9038285 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective auditory attention to deviants in the left ear (ATTL)
Number of subjects: 17
Study 9038285 — intervention group
Group type: COMPARATOR
Intervention: Silent rest (REST)
Number of subjects: 17
Study 8269798 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg 2 times/day for 12 weeks
Number of subjects: 12
Study 31522180 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Citrate Anticoagulation (RCA)
Number of subjects: 64
Study 31522180 — intervention group
Group type: COMPARATOR
Intervention: No-Anticoagulation
Number of subjects: 64
Study 30253689 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental mental-health problems
Number of subjects: 3164
Study 30253689 — intervention group
Group type: EXPERIMENTAL
Intervention: Child mental-health problems
Number of subjects: 3164
Study 30253689 — intervention group
Group type: EXPERIMENTAL
Intervention: Families with at least one individual experiencing mental-health problems
Number of subjects: 3164
Study 30253689 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of parental support and/or psychological health-care services
Number of subjects: 3164
Study 30253689 — intervention group
Group type: COMPARATOR
Intervention: Families without mental-health problems
Number of subjects: 3164
Study 29911379 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (once daily subcutaneous injections)
Number of subjects: 50
Study 29911379 — intervention group
Group type: COMPARATOR
Intervention: Control (no anticoagulation)
Number of subjects: 50
Study 26237831 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular pressing treatment using Semen Vaccariae on auricular points CO10, LO5, TF4, CO15, CO12, and CO13 for three treatment courses
Number of subjects: 72
Study 26237831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 72
Study 23769562 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin combined with cyclosporine A (CsA)
Number of subjects: 76
Study 23769562 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) alone
Number of subjects: 76
Study 21445364 — intervention group
Group type: COMPARATOR
Intervention: Ventilator-associated pneumonia (VAP)
Number of subjects: 600
Study 21445364 — intervention group
Group type: COMPARATOR
Intervention: Ventilator-associated complications (VAC)
Number of subjects: 600
Study 18343739 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line polychemotherapy regimen including oxaliplatin or irinotecan
Number of subjects: 0